2-hexyl-1,4-dioxane | 706-04-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 2-hexyl-1,4-dioxane
• 英文别名: n-Hexyl-1,4-dioxan；2-Hexyl-1,4-dioxan；hexyl-[1,4]dioxane
• CAS: 706-04-7
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: NEVIBJTYLVDKLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,4-二氧六环 、 1-己烯 在 二叔丁基过氧化物 作用下， 反应 1.0h， 以60%的产率得到2-hexyl-1,4-dioxane
  参考文献：
  名称：

  Pastushenko, E. V.; Safiulova, G. I.; Kruglov, D. E., Journal of Organic Chemistry USSR (English Translation), 1991, vol. 27, # 11.2, p. 2143 - 2148

  摘要：

  DOI：

文献信息

• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
  申请人：JAPAN TOBACCO INC.

  公开号：US20140221378A1

  公开（公告）日：2014-08-07

  Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. The present invention relates to a compound represented by the following formula [I] or [II] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.

  提供了一种替代的螺环吡啶并[1,2-a]吡嗪衍生物或其药用盐，其作为一种抗HIV药物。本发明涉及以下式[I]或[II]所表示的化合物或其药用盐： 其中每个符号如规范中定义的那样。
• Method of the solid phase synhesis of pyrrole-imidazole polyamide
  申请人：——

  公开号：US20040171799A1

  公开（公告）日：2004-09-02

  It is intended to provide a method of producing a pyrrole-imidazole polyamide whereby a longer pyrrole-imidazole polyamide can be conveniently synthesized and a peptide (protein) can be easily transferred. According to this method, a pyrrole-imidazole polyamide having a carboxylate group which can be excised from a solid phase carrier at its end, makes it possible to directly transfer various functional groups and can exactly distinguish DNA sequences can be efficiently produced. A method of synthesizing a pyrrole-imidazole polyamide characterized by performing automatic synthesis by the solid phase Fmoc method with the used of a peptide synthesizer; a pyrrole-imidazole polyamide having a carboxyl group at its end obtained by this method; a pyrrole-imidazole polyamide having a DNA alkylation agent transferred into the carboxyl group at the end of the above-described pyrrole-imidazole polyamide; and a sequence-specific DNA alkylation method characterized by using the above compound.

  这是为了提供一种生产吡咯-咪唑聚酰胺的方法，可以方便地合成更长的吡咯-咪唑聚酰胺，并且可以轻松地转移肽（蛋白质）。根据这种方法，一种具有羧基团的吡咯-咪唑聚酰胺可以从固相载体上剪切，从而可以直接转移各种功能基团，并能够精确区分DNA序列，可以高效地生产。这种方法的特点是通过固相Fmoc方法在肽合成仪上进行自动合成吡咯-咪唑聚酰胺；通过这种方法获得具有羧基团的吡咯-咪唑聚酰胺；将DNA烷基化剂转移到上述吡咯-咪唑聚酰胺末端的羧基团的吡咯-咪唑聚酰胺；以及使用上述化合物的特异性DNA烷基化方法。
• [EN] MALONIC ACID DI-SALTS AND A METHOD FOR PREPARING MALONYL DIHALIDES<br/>[FR] DI-SELS D'ACIDE MALONIQUE ET PROCÉDÉ DE FABRICATION DE DIHALOGÉNURES DE MALONYLE
  申请人：DU PONT

  公开号：WO2013090547A1

  公开（公告）日：2013-06-20

  A compound of Formula (2) is disclosed: wherein R1, MA and MB are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula (1): wherein R1 and X are as defined in the disclosure comprising contacting a compound of Formula (2) with a halogenating agent. Also disclosed is a method for preparing a compound of Formula (4): wherein R1, R3 and R4 are as defined in the disclosure, comprising reacting a compound of Formula (5): wherein R3 and R4 are as defined in the disclosure with a compound of Formula (1), with a compound of Formula (1), the process of preparing the compound of Formula (4) includes the step of preparing the compound of Formula (1) from the compound of Formula (2) by the method disclosed above. Also disclosed is compound that is methyl 3,5-dichlorobenzeneethanimidate methyl 3,5 dichlorobenzeneethanimidate or ethyl 3,5 dichlorobenzeneethanimidate or salts thereof.

  揭示了一个化合物的化学式（2）：其中R1、MA和MB如披露所定义。还披露了一种制备化合物的方法的化学式（1）：其中R1和X如披露所定义，包括将化合物的化学式（2）与卤代试剂接触。还披露了一种制备化合物的方法的化学式（4）：其中R1、R3和R4如披露所定义，包括将化合物的化学式（5）：其中R3和R4如披露所定义与化合物的化学式（1）反应，通过从化合物的化学式（2）制备化合物的化学式（1）的方法制备化合物的化学式（4）。还披露了一种化合物，即甲基3,5-二氯苯基乙酰亚胺酸甲酯、甲基3,5-二氯苯基乙酰亚胺酸乙酯或其盐。
• Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
  申请人：Dixit Girish

  公开号：US20110142883A1

  公开（公告）日：2011-06-16

  The present invention relates to stable amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts of the present invention have improved physiochemical characteristics that assist in the effective bioavailability

  本发明涉及阿托伐他汀药物可接受盐与药物可接受辅料的稳定非晶共沉淀物、制备方法、制药组合物及其治疗方法。有益的是，本发明的阿托伐他汀药物可接受盐的非晶共沉淀物具有改善的物理化学特性，有助于有效的生物利用度。